Acumen Pharmaceuticals (ABOS), Monday reported that using a plasma pTau217 screening assay in its Phase?2 ALTITUDE-AD study of sabirnetug reduced trial screening costs by about 40 percent across U.S. and Canadian sites.
Nearly half of volunteers met the pTau217 threshold for confirmatory testing, and 81 percent of those were amyloid-positive minimizing unnecessary PET scans and lumbar punctures and speeding enrollment.
In nonclinical comparisons, sabirnetug demonstrated the strongest binding to toxic amyloid-ß oligomers and minimal affinity for monomers showing an 8,750-fold selectivity for Aß1-42 oligomers over Aß1-40 monomers, outperforming lecanemab and aducanumab.
ABOS is currently trading at $1.53, down $0.0352 or 2.24 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Economic News
What parts of the world are seeing the best (and worst) economic performances lately? Click here to check out our Econ Scorecard and find out! See up-to-the-moment rankings for the best and worst performers in GDP, unemployment rate, inflation and much more.
September 04, 2026 15:08 ET The job report and foreign trade data were the main economic news from the U.S. in the first week of September. Elsewhere in North America, the Canadian central bank announced its latest policy decision. Inflation data from Eurozone was the highlight in Europe. The latest interest rate decision by the Reserve Bank of New Zealand drew attention in Asia.